Literature DB >> 9795767

The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis.

V K Tuohy1, M Yu, L Yin, J A Kawczak, J M Johnson, P M Mathisen, B Weinstock-Guttman, R P Kinkel.   

Abstract

We have made the following observations regarding self-recognition during the development and progression of murine experimental autoimmune encephalomyelitis (EAE) and human multiple sclerosis (MS): 1) chronic progression of EAE is accompanied by a sequential, predictable cascade of neo-autoreactivity, commonly referred to as epitope spreading, presumably caused by endogenous self-priming during autoimmune-mediated tissue damage; 2) there is an invariant relationship between the progression of EAE and the emergence of epitope spreading; 3) progression of EAE can be inhibited by the induction of antigen-specific tolerance to spreading determinants after onset of initial neurologic symptoms; 4) CD4+ Th 1 cells responding to spreading determinants are autonomously encephalitogenic; 5) epitope spreading occurs during the development of MS and in some cases involves HLA-DP class II-restricted self-recognition; and 6) progression of both EAE and MS is accompanied by the decline of primary T-cell autoreactivity associated with disease onset and by the concurrent emergence of the epitope spreading cascade. Our studies directly challenge the traditional view that EAE and MS are initiated and maintained by autoreactivity directed against a single predominant myelin protein or determinant. Our results indicate that progression of EAE and MS involves a shifting of T-cell autoreactivity from primary initiating self-determinants to defined cascades of secondary determinants that sustain the inflammatory self-recognition process during disease progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9795767     DOI: 10.1111/j.1600-065x.1998.tb01211.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  41 in total

Review 1.  Early-stage multiple sclerosis : what are the treatment options?

Authors:  Per Soelberg Sorensen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  Mechanisms regulating regional localization of inflammation during CNS autoimmunity.

Authors:  Emily Pierson; Sarah B Simmons; Luca Castelli; Joan M Goverman
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

3.  Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary involvements.

Authors:  M Yamazaki; R Kitamura; S Kusano; H Eda; S Sato; M Okawa-Takatsuji; S Aotsuka; K Yanagi
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

Review 4.  Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens.

Authors:  J M Boulter; B K Jakobsen
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

5.  After injection into the striatum, in vitro-differentiated microglia- and bone marrow-derived dendritic cells can leave the central nervous system via the blood stream.

Authors:  Sonja Hochmeister; Manuel Zeitelhofer; Jan Bauer; Eva-Maria Nicolussi; Marie-Therese Fischer; Bernhard Heinke; Edgar Selzer; Hans Lassmann; Monika Bradl
Journal:  Am J Pathol       Date:  2008-10-30       Impact factor: 4.307

6.  Progression of relapsing-remitting demyelinating disease does not require increased TCR affinity or epitope spread.

Authors:  Anna E Kersh; Lindsay J Edwards; Brian D Evavold
Journal:  J Immunol       Date:  2014-09-29       Impact factor: 5.422

7.  Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates.

Authors:  Ryan M Pearson; Liam M Casey; Kevin R Hughes; Leon Z Wang; Madeleine G North; Daniel R Getts; Stephen D Miller; Lonnie D Shea
Journal:  Mol Ther       Date:  2017-05-05       Impact factor: 11.454

8.  Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis.

Authors:  Yonghao Cao; Brittany A Goods; Khadir Raddassi; Gerald T Nepom; William W Kwok; J Christopher Love; David A Hafler
Journal:  Sci Transl Med       Date:  2015-05-13       Impact factor: 17.956

Review 9.  Modeling the heterogeneity of multiple sclerosis in animals.

Authors:  Sarah B Simmons; Emily R Pierson; Sarah Y Lee; Joan M Goverman
Journal:  Trends Immunol       Date:  2013-05-21       Impact factor: 16.687

Review 10.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.